Search results for: Precision Medicine
Filter search results
Annual Lecture Publication Now Available
16 November 2010
Now available is the full text of Dr Alan Garber’s remarks at the OHE Annual Lecture. Each year, the OHE sponsors a lecture that explores a timely issue in medicine…
Controlling NHS Expenditure: The Impact of Labour’s NHS White Papers
1 December 1998
…Family Health Services (FHS) medicines bill, i.e. including for the first time the cost of medicines prescribed for NHS patients by non-fundholding GPs, may be intended to serve two main…
Cost and Benefits of Pharmaceutical Research
1 May 1987
…in parallel with the advances in medicine itself. New ways of looking at the outcome of medical progress are having to be developed in order to quantify the benefits which…
Spotlight on OHE: Recent Awards, Publications and Presentations
12 September 2012
…Policy. 17(3), 157-164. Presentations on stratified medicine and R&D discontinuation decisions In July, Martina Garau presented at the University of Liverpool’s conference, The Science of Stratified Medicine. The event brought…
Advances in Oncology Modelling: Recent Results from POI Research
18 September 2012
…government. The focus of the workshop was three key technical challenges associated with using clinical trial data for anti-cancer medicines and adapting it, in an unbiased fashion, to support decisions…
Spotlight on OHE: Understanding Value Based Pricing
12 February 2013
…to valuing genomic medicines. Value based pricing (VBP) is increasingly common in health care systems worldwide. OHE continues to make important contributions to the debate about VBP approaches and application…
Around The World in HTAs: Türkiye – The bumpy road toward transformation
31 January 2024
…established in 2012 and was later re-named as Research Development and Health Technology Assessment Department (HTAD). Additionally, the Turkish Medicines and Medical Devices Agency (TMMDA) and the HTA department within…
Performance-Based Risk Sharing in Health Care: Current Status
17 April 2013
Performance-based risk sharing arrangements for prescription medicines and other treatments are attractive to payers because they promise to base what is paid for a treatment on whether/how well it actually…
Dr. Sabine Vogler
4 September 2024
…Expert Panel in 2020) and has been involved in the WHO Oslo Medicines Initiative (Novel Medicines Platform) and is member of the Technical Advisory Group on Pricing Policies for Medicines…..